Mitogen Induced Production of Polyclonal IgG is Decreased in Women With Severe Endometriosis
Version of Record online: 9 MAY 2013
American Journal of Reproductive Immunology
Volume 29, Issue 2, pages 124–130, March 1993
How to Cite
GEBEL, H. M., BRAUN, D. P., ROTMAN, C., RANA, N. and DMOWSKI, W. P. (1993), Mitogen Induced Production of Polyclonal IgG is Decreased in Women With Severe Endometriosis. American Journal of Reproductive Immunology, 29: 124–130. doi: 10.1111/j.1600-0897.1993.tb00576.x
- Issue online: 9 MAY 2013
- Version of Record online: 9 MAY 2013
- Accepted January 21, 1993
- Gonadotropin releasing hormone
PROBLEM: The etiology and/or pathogenesis of endometriosis may involve aspects of both humoral and cellular immunity.
METHOD: In this investigation, we analyzed the ability of B lymphocytes from distinct patient groups for production of IgGl, IgG2, and IgG3 following in vitro stimulation with polyclonal B-cell mitogens (pokeweed mitogen and Staphylococcus aureus Cowan strain I) after in vitro stimulation with polyclonal B-cell activators.
RESULTS: We observed that the in vitro production of IgGl, IgG2, and IgG3 was identical among fertile controls (no endometriosis; N = 22), infertile women without endometriosis (N = 22), infertile women without endometriosis (N = 20) and patietns with stage 1 or 2 endometriosis (N = 31). In contrast, in vitro IgG2 production was significantly reduced among women with stage 3 or 4 endometriosis (N = 11) compared to controls (P < 0.001).
CONCLUSION: Since the number of circulating B cells was similar in each patient group studied, the reduced production of IgG2 in patients with stage 3 or 4 disease was not merely due to fewer antibody producing cells in those subjects, and we speculate that the observed decrease in polyclonal IgG2 production among these patients is due to a primary defect. In additional studies, we observed that polyclonal IgG2 production was normal among stage 3 or 4 patients treated with danazol (N=ll), but significantly reduced in patients treated with gonadotropin releasing hormone agonists (N = 8). Although not conclusive, these data suggest that danazol may have the capacity to correct the defective production of polyclonal IgG2 in patients with severe endometriosis.